Wolfe Research Initiates Coverage on Dianthus Therapeutics (NASDAQ:DNTH)

Research analysts at Wolfe Research started coverage on shares of Dianthus Therapeutics (NASDAQ:DNTH) in a report issued on Thursday, MarketBeat.com reports. The firm set an “outperform” rating and a $98.00 price target on the stock. Wolfe Research’s price objective indicates a potential upside of 9.17% from the company’s previous close.

Other equities analysts also recently issued reports about the company. Oppenheimer lifted their target price on Dianthus Therapeutics to $145.00 and gave the company an “outperform” rating in a research note on Monday, March 9th. TD Cowen reaffirmed a “buy” rating on shares of Dianthus Therapeutics in a report on Monday, March 9th. William Blair reaffirmed an “outperform” rating on shares of Dianthus Therapeutics in a report on Monday, March 16th. Wells Fargo & Company started coverage on Dianthus Therapeutics in a report on Thursday, March 19th. They set an “overweight” rating and a $135.00 price target on the stock. Finally, Jefferies Financial Group set a $98.00 price target on Dianthus Therapeutics and gave the company a “buy” rating in a report on Monday, March 9th. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $115.55.

Dianthus Therapeutics Stock Down 2.1%

Shares of DNTH stock opened at $89.77 on Thursday. The business has a 50 day moving average of $67.46 and a two-hundred day moving average of $49.70. Dianthus Therapeutics has a 52 week low of $15.25 and a 52 week high of $92.27. The company has a market cap of $3.99 billion, a P/E ratio of -21.90 and a beta of 1.22.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Monday, March 9th. The company reported ($1.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.46). Dianthus Therapeutics had a negative net margin of 7,973.33% and a negative return on equity of 38.85%. The company had revenue of $0.57 million during the quarter, compared to analyst estimates of $0.40 million. Analysts expect that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.

Insider Transactions at Dianthus Therapeutics

In related news, CEO Marino Garcia sold 122,918 shares of the business’s stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $81.49, for a total transaction of $10,016,587.82. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Ryan Savitz sold 8,224 shares of the business’s stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $89.84, for a total value of $738,844.16. Following the sale, the executive vice president directly owned 8,224 shares in the company, valued at approximately $738,844.16. The trade was a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 323,021 shares of company stock worth $26,564,008 in the last three months. 8.15% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Dianthus Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Parkside Financial Bank & Trust raised its holdings in Dianthus Therapeutics by 131.7% during the third quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock worth $37,000 after purchasing an additional 540 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in Dianthus Therapeutics during the fourth quarter worth approximately $40,000. Raymond James Financial Inc. bought a new stake in Dianthus Therapeutics during the second quarter worth approximately $27,000. Russell Investments Group Ltd. bought a new stake in Dianthus Therapeutics during the third quarter worth approximately $64,000. Finally, Royal Bank of Canada raised its holdings in shares of Dianthus Therapeutics by 36.9% in the 4th quarter. Royal Bank of Canada now owns 2,012 shares of the company’s stock worth $82,000 after purchasing an additional 542 shares in the last quarter. Institutional investors own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.